IL183810A0 - Use of ppar agonists for the treament of congestive heart failure - Google Patents

Use of ppar agonists for the treament of congestive heart failure

Info

Publication number
IL183810A0
IL183810A0 IL183810A IL18381007A IL183810A0 IL 183810 A0 IL183810 A0 IL 183810A0 IL 183810 A IL183810 A IL 183810A IL 18381007 A IL18381007 A IL 18381007A IL 183810 A0 IL183810 A0 IL 183810A0
Authority
IL
Israel
Prior art keywords
treament
heart failure
congestive heart
ppar agonists
ppar
Prior art date
Application number
IL183810A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of IL183810A0 publication Critical patent/IL183810A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL183810A 2004-12-17 2007-06-10 Use of ppar agonists for the treament of congestive heart failure IL183810A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04029946A EP1671633A1 (en) 2004-12-17 2004-12-17 Use of PPAR agonists for the treatment of congestive heart failure
PCT/EP2005/013046 WO2006063715A1 (en) 2004-12-17 2005-12-06 Use of ppar agonists for the treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
IL183810A0 true IL183810A0 (en) 2007-10-31

Family

ID=34927823

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183810A IL183810A0 (en) 2004-12-17 2007-06-10 Use of ppar agonists for the treament of congestive heart failure

Country Status (16)

Country Link
US (1) US7601863B2 (enExample)
EP (2) EP1671633A1 (enExample)
JP (1) JP2008524129A (enExample)
KR (1) KR20070086332A (enExample)
CN (1) CN101072557A (enExample)
AR (1) AR051723A1 (enExample)
AT (1) ATE498400T1 (enExample)
AU (1) AU2005315920A1 (enExample)
BR (1) BRPI0519661A2 (enExample)
CA (1) CA2590391A1 (enExample)
DE (1) DE602005026443D1 (enExample)
IL (1) IL183810A0 (enExample)
MX (1) MX2007006678A (enExample)
MY (1) MY141010A (enExample)
TW (1) TW200635584A (enExample)
WO (1) WO2006063715A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399777B2 (en) 2001-08-31 2008-07-15 Sanofi-Aventis Deutschland Gmbh Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
PL3523283T3 (pl) 2016-10-05 2021-12-13 Mitobridge, Inc. Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101070316A (zh) * 1999-04-28 2007-11-14 萨诺费-阿文蒂斯德国有限公司 作为ppar受体配体的二芳基酸衍生物
IL160556A0 (en) * 2001-08-31 2004-07-25 Aventis Pharma Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
WO2004082621A2 (en) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Novel ppar agonists, pharmaceutical compositions and uses thereof
US6989462B2 (en) * 2003-03-25 2006-01-24 Sanofi-Aventis Deutschland Gmbh Synthesis of 2-chloromethyl-6-methylbenzoic ester
US6987118B2 (en) * 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators

Also Published As

Publication number Publication date
US7601863B2 (en) 2009-10-13
WO2006063715A1 (en) 2006-06-22
DE602005026443D1 (de) 2011-03-31
EP1827425B1 (en) 2011-02-16
EP1827425A1 (en) 2007-09-05
KR20070086332A (ko) 2007-08-27
AR051723A1 (es) 2007-01-31
TW200635584A (en) 2006-10-16
MX2007006678A (es) 2007-08-14
CN101072557A (zh) 2007-11-14
MY141010A (en) 2010-02-25
EP1671633A1 (en) 2006-06-21
US20080039512A1 (en) 2008-02-14
BRPI0519661A2 (pt) 2009-03-03
AU2005315920A1 (en) 2006-06-22
JP2008524129A (ja) 2008-07-10
CA2590391A1 (en) 2006-06-22
ATE498400T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
GB2423107B (en) Apparatus for the creation of outer surfaces for structures
GB2434097B (en) New use for cannabinoid
EP1964575A4 (en) PHARMACEUTICAL AGENT WITH A PPAR AGONIST
GB0908173D0 (en) Process for facilitating the management of care
PL1824523T3 (pl) Sposób obrazowania serca przy zastosowaniu hiperspolaryzowanego 13C-pirogronianu
EP1803830A4 (en) HART METALS
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
IL180721A0 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
HU0401522D0 (en) New 4-benzylidene-piperidine derivatives
SI1539746T1 (sl) Spojine n-substituirane-1h-indol-5-propionske kisline kot agonisti ppar, ki so uporabne za zdravljenje diabetesa
EP1713815A4 (en) PTH AGONISTS
ZA201005306B (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
IL183810A0 (en) Use of ppar agonists for the treament of congestive heart failure
PL2366393T3 (pl) Roflumilast do leczenia nadciśnienia płucnego
EP1713782A4 (en) PTH AGONISTS
PL1638591T3 (pl) Agoniści SLRP klasy III do stosowania w ograniczeniu tworzenia naczyń krwionośnych
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
GB2422858B (en) Downhole swivel joint
PT1849360E (pt) Novo uso para ácido 2-hidroxi-4-metiltiobutanóico (hmtb)
GB0526552D0 (en) New use
EP1881580A4 (en) DC-DC CONVERTER
ITRM20050248A1 (it) Uso acido adamantil metossidifenil propenoico per il trattamento di patologie cutanee.
GB2420857B (en) Corrosion monitoring probe
ITRM20090336A1 (it) Apparato d'appoggio, particolarmente per wellness, adatto a supportare il corpo di un utilizzatore.
EP1882150A4 (en) BELT